<DOC>
	<DOCNO>NCT01897701</DOCNO>
	<brief_summary>This randomize , observer-blinded , placebo-controlled trial adult ≥18 year old . Randomization stratify age ( 18 49 year ≥50 year ) prior influenza immunization within past three month . Proportions subject various strata pre-specified ; rather , goal achieve approximately equal distribution subject characteristic across various treatment group . Treatments comprise two identical IM dose 21-day interval ( Day 0 Day 21 ) , alternate deltoid . For subject , study follow-up span approximately 385 day total , approximately 13 month first dose .</brief_summary>
	<brief_title>A ( H7N9 ) VLP Antigen Dose Ranging Study With Adjuvant 1</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<criteria>Subjects must meet follow eligible participation study : 1 . Healthy adult male female , ≥18 year age , 2 . Willing able give inform consent prior study enrollment , 3 . Able comply study requirement , 4 . Women childbearing potential must negative urine pregnancy test prior vaccination , advise Informed Consent process avoid become pregnant duration study , must assert employ effective form birth control duration study . Acceptable form birth control : credible history continuous abstinence heterosexual activity prior surgical sterilization , hormonal contraceptive ( oral , injectable , implant , patch , ring ) , barrier contraceptive ( condom diaphragm ) , intrauterine device ( IUD ) . Women adequately document history surgical sterility , ≥50 year age without menses ≥ 1 year exempt urine pregnancy test . Subjects meet follow criterion eligible participation study . 1 . Any ongoing , symptomatic acute chronic illness require medical surgical care . Asymptomatic condition finding ( e.g. , mild hypertension , dyslipidemia ) associate evidence endorgan damage exclusionary provide appropriately manage clinically stable ( i.e. , unlikely result symptomatic illness within timecourse study ) opinion investigator . Note illness condition may exclusionary , even otherwise stable , due therapy use treat ( see exclusion criterion 2 , 5 , 7 , 8 ) . 2 . Participation research involve investigational product ( drug / biologic / device ) within 45 day plan date first vaccination . 3 . History serious reaction prior influenza vaccination . 4 . History GuillainBarré Syndrome ( GBS ) within 6 week follow previous influenza vaccine . 5 . Received vaccine 4 week precede study vaccination ; A ( H7N9 ) avian influenza vaccine time . 6 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 7 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10 mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 8 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 9 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature &gt; 38.0°C planned day vaccine administration ) . 10 . Known disturbance coagulation . 11 . Women pregnant breastfeeding , plan become pregnant study . 12 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse . 13 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic psychiatric condition deem likely impair quality safety reporting ) . 14 . Persons employ capacity involve handle poultry wild bird .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>H7N9</keyword>
</DOC>